Ketamine for the treatment of depressive and negative symptoms in patients with schizophrenia: a randomized controlled cross-over pilot study.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519097-39-01

Enrollment

Registered

2025-02-27

Start date

2022-06-23

Completion date

Unknown

Last updated

2025-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Negative and depressive symptoms in schizophrenia / schizoaffective disorder

Brief summary

Change from baseline in Brief Negative Symptoms Scale (BNSS) scores after two weeks of treatment with esketamine or active placebo (diphenhydramine), Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) scores after two weeks of treatment with esketamine or active placebo

Interventions

DRUGDibondrin - Ampullen

DRUGKetanest® S 25 mg/ml - Ampullen

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change from baseline in Brief Negative Symptoms Scale (BNSS) scores after two weeks of treatment with esketamine or active placebo (diphenhydramine), Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) scores after two weeks of treatment with esketamine or active placebo	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026